Leiden, The Netherlands, 23 December 2021 – Fibriant, a scale-up biotech company focused onthe development of the RECOFIB platform, was […]
Fibriant expands license adding recombinant human (pro)thrombin to existing recombinant fibrinogen capability – Company on track for clinical studies with RecoSeelTM in mild-to-moderate bleeding in 2021
Leiden, The Netherlands, December 5, 2019 – Fibriant B.V., a developer of innovative recombinant fibrin(ogen) technology and products, today announced […]
Fibriant CEO Jaap Koopman to present at the 11th annual Biotech Showcase event 2019 on January 7 at 4.30 PM in the Hilton San Francisco Union Square in San Francisco, CA, USA.
Fibriant will provide an up-date on the progress with the development of their recombinant Fibrinogen technology platform and the product […]
Presentation by Prof. Matthew Flick at the 25th International Fibrinogen Research Society meeting in Winston-Salem, NC, USA.
Prof. Flick, a leader in the field of Fibrinogen and host-defense, will present, also on behalf of Fibriant, new data […]
Fibriant and Biomed Elements announce collaboration to develop a new topical hemostat product to stop severe bleeding supported by a MIT grant from the province of Zuid Holland, The Netherlands.
Fibriant and Biomed Elements have entered into a research collaboration, combining their fibrinogen and biopolymer technologies, to develop a topical […]